JHIU
NBIX icon

Janus Henderson Investors US’s Neurocrine Biosciences NBIX Stock Holding History

Janus Henderson Investors US’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$189M Buy
4,359,384
+2,002,899
+85% +$85.8M 0.15% 188
2016
Q4 		$91.2M Buy
2,356,485
+224,906
+11% +$10.2M 0.08% 318
2016
Q3 		$108M Sell
2,131,579
-34,994
-2% -$1.74M 0.09% 283
2016
Q2 		$98.5M Sell
2,166,573
-65,012
-3% -$2.99M 0.08% 291
2016
Q1 		$88.3M Buy
2,231,585
+276,677
+14% +$11M 0.08% 309
2015
Q4 		$111M Buy
1,954,908
+392,259
+25% +$19.9M 0.09% 266
2015
Q3 		$62.2M Sell
1,562,649
-179,780
-10% -$8.69M 0.06% 371
2015
Q2 		$83.2M Buy
1,742,429
+397,828
+30% +$16.9M 0.07% 339
2015
Q1 		$53.4M Buy
1,344,601
+68,237
+5% +$2.44M 0.04% 439
2014
Q4 		$28.5M Buy
1,276,364
+277,209
+28% +$5.25M 0.02% 546
2014
Q3 		$15.7M Buy
999,155
+277,667
+38% +$4.15M 0.01% 620
2014
Q2 		$10.7M Buy
721,488
+47,824
+7% +$675K 0.01% 666
2014
Q1 		$10.8M Sell
673,664
-44,638
-6% -$764K 0.01% 657
2013
Q4 		$6.71M Sell
718,302
-283,657
-28% -$2.77M 0.01% 726
2013
Q3 		$11.3M Buy
+1,001,959
New +$13.8M 0.01% 626

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Investors US's NBIX Position: Q1 2017 in Review

Janus Henderson Investors US increased its Neurocrine Biosciences (NBIX) stake by 85% in Q1 2017, buying an estimated $85.8M and bringing the position to 4,359,384 shares worth $189M. The position accounts for 0.15% of the portfolio, ranked #188.

Janus Henderson Investors US first reported a position in NBIX in Q3 2013 and has held it in 15 quarters since. 218 funds tracked by Wall St. Rank hold NBIX as of Q1 2017.

  • Janus Henderson Investors US held 4,359,384 shares of Neurocrine Biosciences worth $189M as of Q1 2017.
  • Janus Henderson Investors US bought 2,002,899 Neurocrine Biosciences shares in Q1 2017, an estimated $85.8M.
  • Neurocrine Biosciences made up 0.15% of Janus Henderson Investors US's portfolio in Q1 2017, its #188 holding.
  • Janus Henderson Investors US first reported a position in Neurocrine Biosciences in Q3 2013 and has held it in 15 quarters since.
  • 218 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2017.

Based on Janus Henderson Investors US's 13F filing for Q1 2017, filed 16 May 2017.